Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?
Open Access
- 1 June 2009
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 296 (6), G1299-G1306
- https://doi.org/10.1152/ajpgi.00011.2009
Abstract
Corticotropin releasing factor (CRF), a mediator of stress response, alters gastrointestinal (GI) functions. Stress-related changes in colonic motility are blocked by selective CRF1 receptor antagonists. Our aim was to assess whether modulation of central and peripheral CRF1 receptors affects colonic transit and bowel function in female patients with diarrhea-predominant irritable bowel syndrome (D-IBS). This randomized, double-blind, placebo-controlled, 2-wk study evaluated the effects of oral pexacerfont (BMS-562086), a selective CRF1 receptor antagonist, 25 and 100 mg qd, on GI and colonic transit of solids [by validated scintigraphy with primary end point colonic geometric center (GC) at 24 h] and bowel function (by validated daily diaries) in 39 women with D-IBS. The 100-mg dose was comparable to a dose that inhibited colonic motility in stressed rats. Treatment effects were compared by analysis of covariance with baseline colonic transit as covariate. The study had 80% power (α = 0.05) to detect clinically meaningful (26%) differences in colonic transit. Thirty-nine of 55 patients fulfilled eligibility criteria (9 screen failures, 5 baseline GC24 outside prespecified range). At baseline, three treatment groups had comparable age, body mass index, and GC 24 h. Significant effects of pexacerfont relative to placebo were not detected on colonic GC24 ( P = 0.53), gastric emptying, orocecal transit, ascending colon emptying half-time, and stool frequency, consistency, and ease of passage. No safety issues were identified. We conclude that in women with D-IBS, pexacerfont, 25 or 100 mg qd, does not significantly alter colonic or other regional transit or bowel function. The role of central and peripheral CRF1 receptors in bowel function in D-IBS requires further study.Keywords
This publication has 51 references indexed in Scilit:
- Dysregulation of the hypothalamic‐pituitary‐adrenal (HPA) axis in irritable bowel syndromeNeurogastroenterology & Motility, 2009
- Prospective Study of Motor, Sensory, Psychologic, and Autonomic Functions in Patients With Irritable Bowel SyndromeClinical Gastroenterology and Hepatology, 2008
- Gender Difference in Age-Related Number of Corticotropin-Releasing Hormone-Expressing Neurons in the Human Hypothalamic Paraventricular Nucleus and the Role of Sex HormonesNeuroendocrinology, 2007
- Irritable Bowel SyndromeDrugs, 2006
- Corticotropin‐releasing factor 1 receptor‐mediated mechanisms inhibit colonic hypersensitivity in ratsNeurogastroenterology & Motility, 2005
- Role of peripheral CRF signalling pathways in stress‐related alterations of gut motility and mucosal functionNeurogastroenterology & Motility, 2004
- Stool Form Scale as a Useful Guide to Intestinal Transit TimeScandinavian Journal of Gastroenterology, 1997
- Corticotropin Releasing Factor (CRF) increases post‐prandial duodenal motor activity in humansNeurogastroenterology & Motility, 1992
- Increased colonic motility during exposure to a stressful situationDigestive Diseases and Sciences, 1985
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983